Becky J Parks, MD

Associate Professor of Neurology



Additional Titles

  • Co-Director, Comprehensive Multiple Sclerosis Center

Board Certifications

  • Clinical Neurophysiology - Certified
  • Neurology - Certified
  • Psychiatry - Certified

Related Links


  • Teaching Attending of the Year, Department of Neurology, St. Louis University, 1998


  • Fenoglio C, Ridolfi E, Cantoni C, De Riz M, Bonsi R, Serpente M, Villa C, Pietroboni AM, Naismith RT, Alvarez E, Parks BJ, Bresolin N, Cross AH, Piccio LM, Galimberti D, Scarpini E. Decreased circulating miRNA levels in patients with primary progressive multiple sclerosis. Mult Scler. 2013 Dec;19(14):1938-42.
  • Longbrake EE, Parks BJ, Cross AH. Monoclonal antibodies as disease modifying therapy in multiple sclerosis. Curr Neurol Neurosci Rep. 2013 Nov;13(11):390.
  • Alvarez E, Piccio L, Mikesell RJ, Klawiter EC, Parks BJ, Naismith RT, Cross AH. CXCL13 is a biomarker of inflammation in multiple sclerosis, neuromyelitis optica, and other neurological conditions. Mult Scler. 2013 Aug;19(9):1204-8.
  • Waubant E, Pelletier D, Mass M, Cohen JA, Kita M, Cross A, Bar-Or A, Vollmer T, Racke M, Stüve O, Schwid S, Goodman A, Kachuck N, Preiningerova J, Weinstock-Guttman B, Calabresi PA, Miller A, Mokhtarani M, Iklé D, Murphy S, Kopetskie H, Ding L, Rosenberg E, Spencer C, Zamvil SS; ITN STAyCIS Study Group; ITN020AI Study Management Team. Randomized controlled trial of atorvastatin in clinically isolated syndrome: the STAyCIS study. Neurology. 2012 Apr 10;78(15):1171-8.
  • Comi G, Cohen JA, Arnold DL, Wynn D, Filippi M; FORTE Study Group. Phase III dose-comparison study of glatiramer acetate for multiple sclerosis. Ann Neurol. 2011 Jan;69(1):75-82.
  • Klawiter EC, Benzinger T, Roy A, Naismith RT, Parks BJ, Cross AH. Spinal cord ring enhancement in multiple sclerosis. Arch Neurol. 2010 Nov;67(11):1395-8.
  • Piccio L, Naismith RT, Trinkaus K, Klein RS, Parks BJ, Lyons JA, Cross AH. Changes in B- and T-lymphocyte and chemokine levels with rituximab treatment in multiple sclerosis. Arch Neurol. 2010 Jun;67(6):707-14.
  • Naismith RT, Piccio L, Lyons JA, Lauber J, Tutlam NT, Parks BJ, Trinkaus K, Song SK, Cross AH. Rituximab add-on therapy for breakthrough relapsing multiple sclerosis: a 52-week phase II trial. Neurology. 2010 Jun 8;74(23):1860-7.
  • De Riz M, Galimberti D, Fenoglio C, Piccio LM, Scalabrini D, Venturelli E, Pietroboni A, Piola M, Naismith RT, Parks BJ, Fumagalli G, Bresolin N, Cross AH, Scarpini E. Cerebrospinal fluid progranulin levels in patients with different multiple sclerosis subtypes. Neurosci Lett. 2010 Jan 22;469(2):234-6.
  • Pachner AR, Warth JD, Pace A, Goelz S; INSIGHT investigators. Effect of neutralizing antibodies on biomarker responses to interferon beta: the INSIGHT study. Neurology. 2009 Nov 3;73(18):1493-500.
  • Piccio L, Naismith R, Trinkaus K, Klein R, Parks B, Lyons J, Cross A. B cell depletion with rituximab leads to decreased CXCL13 and CCL19 in the cerebrospinal fluid of relapsing multiple sclerosis patients. Submitted 2009, Brain
  • Spinal Cord Ring Enhancement in Multiple Sclerosis: Imaging and Clinical Characteristics. Klawiter E, et al. Submitted, Neurology Apr 2009
  • Klawiter MD, Eric C; Alvarez, III MD PhD, Enrique; Xu PhD, Junqian; Paciorkowski MD, Alex R; Zhu MD PhD, Lirong; Parks MD, Becky J; Cross MD, Anne H; Naismith MD, Robert T. NMO-IgG Detected in CSF in Seronegative Neuromyelitis Optica. Neurology, 2009 Mar 24;72 (12):1101-3.
  • Fenoglio C, Scalabrini D, Piccio L, De Riz M, Venturelli E, Cortini F, Villa C, Serpente M, Parks B, Rinker J, Cross AH, Bresolin N, Scarpini E, Galimberti D. Candidate gene analysis of selectin cluster in patients with multiple sclerosis. J. Neurol. 2009 Feb 25.
  • Rauchway AC, Kaiboriboon K, Bansal SK, Kulkantrakorn K, Guo X, Parks BJ, Hayat G. A role for functional classification in the early identification of prognostic factors in ALS. Amyotrophic Lateral Sclerosis. 2007 Aug; 8(4):214-16.

Dr. Parks is the only part-time faculty member in the Department of Neurology. She spends approximately 40% of her time on direct patient care and 40% of her time as principle or co-investigator in several ongoing clinical trials for multiple sclerosis treatment.